Earnings call transcript: Kamada tops Q3 2026 profit view, shares rise premarket

Kamada reported Q3 2026 adjusted EPS of $0.14 versus $0.13 consensus, while revenue of $52.03 million missed the $52.76 million estimate by 1.38%; shares rose 1.94% premarket to $7.37. Quarterly revenue grew 11% year over year, net income rose 51% to $8 million, and adjusted EBITDA increased 30% to $15.2 million; nine-month operating cash flow more than doubled to $37.6 million. Management raised 2026 guidance to $205–$208 million in revenue and $52–$54 million in adjusted EBITDA, and projected double-digit growth in 2027. Kamada declared a $0.14-per-share Q4 dividend, bringing projected 2026 dividend payments to approximately $32.2 million.

Analysis

The key debate is earnings quality, not the small EPS/revenue variance. KEDRAB demand can support KMDA’s near-term growth, but distributor orders above contractual minimums are not the same as a durable step-up in end-user demand; CDC utilization and subsequent order cadence are the useful checks. GRFS is a relevant competitive exposure, though the call provides no evidence that KMDA’s share gains are coming directly at its expense.

There is also a mix-versus-margin tension: distribution is expanding, but revenue growth there need not translate into comparable profit growth. Meanwhile, the proposed vertical-integration benefit remains prospective—plasma sales have only begun and specialty plasma still requires validation. Do not capitalize those benefits into the thesis until reported margins demonstrate them. The annual EBITDA range also implies lower Q4 EBITDA than Q3, despite full-year revenue guidance requiring Q4 revenue modestly above Q3; that makes mix, launch costs and spending worth testing against the January 2027 outlook.

The immediate reaction looks restrained rather than a clear re-rating signal. Over 1–3 months, the catalysts are Q4 delivery and 2027 guidance; over 6–18 months, biosimilar launches, plasma utilization and any M&A could diversify growth, but add execution and capital-allocation risk. Contrarian point: the bullish story may underweight concentration in a few plasma products and treat management’s unverified demand and pipeline claims as realized earnings. No valuation-based upside conclusion is warranted from the supplied data.

Key Decisions for Investors

• KMDA: prefer a staged, modest long rather than chasing the initial reaction; add only if January guidance supports continued profitable growth and reported results confirm cash conversion. Thesis breaks on a guidance reduction, weakening KEDRAB order cadence, or sustained deterioration in gross/EBITDA margins.
• Track Q4 revenue and adjusted EBITDA together: the guidance ranges imply revenue modestly above Q3 but EBITDA below Q3. If the gap reflects adverse mix or launch/investment costs, temper the earnings multiple; if margins hold despite growth, the quality of the expansion improves.
• Keep GRFS as a competitive monitor, not a short: the article does not establish share loss, pricing pressure or financial exposure sufficient for a relative-value trade. Revisit only with independent evidence of KMDA share gains or displacement in the rabies immunoglobulin market.
• Treat plasma integration and biosimilar targets as watch items, not current earnings credit. Verify validation milestones, realized plasma revenue/margins and launch adoption; delays or M&A funded at the expense of cash returns would weaken the longer-term case.